After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancerEli Lilly’s RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced Share XAfter Scotland says no, NICE backs Lilly’s Retsevmo for lung cancerhttps://pharmaphorum.com/news/after-scotland-says-no-nice-backs-lillys-retsevmo-for-lung-cancer/
Roche, Blueprint’s RET cancer drug Gavreto cleared in EURoche and Blueprint Medicines have opened a second front in their rivalry with Eli Lilly in RET-mutated cancers, Share XRoche, Blueprint’s RET cancer drug Gavreto cleared in EUhttps://pharmaphorum.com/news/roche-blueprints-ret-cancer-drug-gavreto-cleared-in-eu/
Lilly files Alzheimer’s drug donanemab as Cortexyme rival fails trialEli Lilly has followed through on its plan to file for approval of its Alzheimer’s disease candidate donanemab, Share XLilly files Alzheimer’s drug donanemab as Cortexyme rival fails trialhttps://pharmaphorum.com/news/lilly-files-alzheimers-drug-donanemab-as-cortexyme-rival-fails-trial/
Good news for Lilly as sintilimab hits the spot in lung cancer againEli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent’s Share XGood news for Lilly as sintilimab hits the spot in lung cancer againhttps://pharmaphorum.com/news/good-news-for-lilly-as-sintilimab-hits-the-spot-in-lung-cancer-again/
EU panel rejects Pfizer’s tanezumab for osteoarthritis painAny lingering hope that Pfizer may finally get a regulatory approval for its nerve growth factor (NGF) inhibitor Share XEU panel rejects Pfizer’s tanezumab for osteoarthritis painhttps://pharmaphorum.com/news/eu-panel-rejects-pfizers-tanezumab-for-osteoarthritis-pain/
FDA firms up JAK inhibitor warnings after Xeljanz reviewThe FDA has concluded its safety review of Pfizer’s JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings Share XFDA firms up JAK inhibitor warnings after Xeljanz reviewhttps://pharmaphorum.com/news/fda-firms-up-jak-inhibitor-warnings-after-xeljanz-review/
Lilly taps Lycia for protein degrader tech in $1.6bn dealEli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal Share XLilly taps Lycia for protein degrader tech in $1.6bn dealhttps://pharmaphorum.com/news/lilly-taps-lycia-for-protein-degrader-tech-in-1-6bn-deal/
Jardiance gets parity with Farxiga in US as FDA clears use in heart failureEli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with Share XJardiance gets parity with Farxiga in US as FDA clears use in heart failurehttps://pharmaphorum.com/news/jardiance-gets-parity-with-farxiga-in-us-as-fda-clears-use-in-heart-failure/
With Alzheimer’s market opening up, Lilly forms neuroscience unitEli Lilly is one of the front runners in the bid to follow Biogen and Eisai onto the Share XWith Alzheimer’s market opening up, Lilly forms neuroscience unithttps://pharmaphorum.com/news/lilly-forms-neuroscience-unit/
